Capital International Sarl Zai Lab LTD Transaction History

Capital International Sarl

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$22.72 - $31.49 $1.09 Million - $1.51 Million	-47,845 Reduced 73.41%	17,328 $421,000
Q2 2023 Aug 11, 2023	SELL	$25.3 - $39.67 $2.96 Million - $4.64 Million	-116,963 Reduced 64.22%	65,173 $1.81 Million
Q1 2023 May 15, 2023	BUY	$30.21 - $48.1 $924,577 - $1.47 Million	30,605 Added 20.2%	182,136 $6.06 Million
Q3 2022 Nov 14, 2022	SELL	$34.2 - $51.69 $158,619 - $239,738	-4,638 Reduced 2.97%	151,531 $5.18 Million
Q2 2022 Aug 15, 2022	BUY	$23.14 - $49.68 $88,996 - $191,069	3,846 Added 2.52%	156,169 $5.42 Million
Q1 2022 May 16, 2022	BUY	$27.77 - $64.4 $4.23 Million - $9.81 Million	152,323 New	152,323 $6.7 Million

123

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.55B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

Stay updated on Capital International Sarl with notifications on news.